Dec 9th, 2013

Nagib M. WARD, Executive VP

BIO PACIFIC RIM SUMMIT

DEINOCOCCUS

A NEW SCIENTIFIC AND TECHNOLOGICAL OPPORTUNITY

2

• Deinove holds the largest collection of Deinococci in the world (6,000 strains)

• A proprietary technological platform (16 patents) with validation through a POC (DEINOL)

Num

ber

of public

ations

200

000

100

000

300

000

Microorganisms

NUMBER OF PUBLICATIONS PER

GENUS

Num

ber

of pate

nts

4 000

0

8 000

Microorganisms

NUMBER OF PATENTS PER

GENUS

Escherichia coli

Saccharomyces

cerevisiae

Deinococcus

Deinococcus

geothermalis

The world pioneer in deinotechnologies and their IP.

DEINOVE

D. radiodurans discovered in 1956, by accident.

Pr. Miroslav Radman: DNA repair research.

Industrial tool: Deinove creation in 2006.

DEINOCOCCUS GENUS

DEINOVE

CORPORATION KEY DATES

4

2009 2007 2008

Inception, co-founders Pr Miroslav RADMAN Dr Philippe POULETTY

2013 2006 2010

DEINOL

EC1

2011 2012

OSEO funding (€1.57 m)

Jacques BITON CEO

IPO (€12 m) Partnership with TEREOS Partnership with VTT OSEO funding (€1.4 m)

OSEO funding (€6 m)

Deinobank (6 000 strains) Initiation of DEINOL program

Deinobank (25 strains)

Proprietary technological platform Initiation of DEINOBIOTICS program

Initiation of DEINOCHEM program

DEINOL EC2 (POC) THANAPLAST™ program

DEINOBIOTICS SAS

OSEO funding (€1.15 m) Market Cap: €53 m 30 FTE

Emmanuel PETIOT CEO Nagib WARD Exec VP

2 5 31 Staff

DEINOVE

Diverse environments have been targeted…

…unusual selection by irradiation

…unusual carbon sources

Deinococcus library (1800 strains) AND diverse library of original strains (4200)

All strains collected according to the international laws (CBD)

Source of original new biocatalysts

6000 STRAINS LIBRARY, MANY UNSUAL

5

DEINOVE RESEARCH CENTER

BIOPÔLE EUROMÉDECINE IN MONTPELLIER, FRANCE

6

+40 EMPLOYEES 1000 m2

DEINOVE

SSCF PROCESS

7

DEINOVE

Operating at 47-52C allows maximizing enzymes at their biochemical optimum, minimizing doses.

INDUSTRIAL ADVANTAGES

8

CBP: enzymes are excreted in solutions to boost digestion, accelerate cofermentation

An polyextremophile with remarkable resistance to harsh conditions or toxic substances.

Metabolizes C3s but also

coassimilates C6 and C5s.

Outstanding molecular biology tool to express

specific sequences:

• Enzymes

• Metabolic Pathways

Vast IP opportunities for a largely unknown and

underutilized bacterial strain.

DEINOVE

Higher temperature (~50C):

• Lower infection rates/risks

• Lower enzyme dose by leveraging biochemical optimums Inhibitors/Products resistance:

• Allows utilizing cellulosic sugars

• Maximizes product yields Molecular Transformation:

• Express proprietary sequences.

• Introduce new metabolic pathways CBP/Enzyme release:

• Significantly affect conversion/hydrolysis costs

• Promote optimal process type: SSF IP Opportunities:

• Vastly unfiled IP field.

PROCESS BENEFITS IN INDUSTRY

9

Deinococcus ficus Deinococcus aquaticus Deinococcus daejeonensis

Roseomonas aestuarii

Deinococcus marmoris

Rhodococcus corynebacterioides

Kocuria turfanensis

PIGMENTED BACTERIA BIODIVERSITY : PINK, ORANGE AND RED PIGMENTS

3: Feedstock

1: Main Product

2: Co-Product

4: Process

Benefits

DEINOVE

BUSINESS MODEL

DEINOVE

COMMERCIAL STRUCTURE

Deinol

Green Solvents Biofuels

Deinochem

Renewable Chemicals

Nutraceuticals Deinomediation

ThanaPlastTM

Deinobiotics

DEINOVE

ETHANOL

MARKETS AND PRODUCTS

13

ADVANCED

BIOFUELS

RENEWABLE CHEMICALS &

INTERMEDIATES

ADVANCED CHEMICALS

SUGARS AND PREBIOTICS

HIGH-VALUE

INTERMEDIATES

BIODIGESTION

THE DEINO WAY TO RENEWABLE CHEMICALS

14

DEINOCHEM

Our biochemical platforms leverage Deinoccocus’ advantageous properties in industrial settings:

• The extreme robustness of the bacterial strains

• Their feedstock flexibility and usage efficiency

• The genetic modification efficiency and optimization of

DEINOVE’s strains

These properties are key success factors for DEINOVE’s targeted industrial applications, by: allowing a customization of the platforms for each commercial partner

being independent of either the starting feedstock or pretreatment technology employed

OUR GREEN BIOTRANSFORMING PLATFORM

15

HO

O

OHHO

HO

HO

DEINOCHEM

BIOMASS VALUE GENERATION

16

C3, C5 & C6 Sugars Conversion

HO

O

OHHO

HO

AcCoA

AcetoAcCoA

hydroxybutyrylCoA

crotonylCoA

butyrylCoA

MalonylCoA

H3C OH

Butanol

H3C CH3

CH3

OH

H3C CH3

HO

H3C

CH2

H2C CH3

CH2

Geraniol Linalol Isoprene

H3COH

O

NH2

OH

O

O

H3C

OH

O

O

H3C CH3

O

HO

O

CH2

H3C OH

H3C CH3

OH

H3C

H3C

CH2

StyrEne

Isobutanol

Butanol

Isobutene

H2C

O

OH

Diaminobutane

Acrylate

NH2H2N

Solvents

Paints

Plastics

Dispersants

Cosmetic

Speciality Chemicals

FERMENTATION PATH

AMINO ACIDS DERIVED PATHWAYS

ISOPRENOÏDS

Renewable

biochemicals

DEINOREDUCTION Nutraceuticals

Solvents

DEINOVE

BIOTRANSFORMATION

Specific molecular biology tools are

necessary to biotransform Deinove’s

strains.

Exact location genetic insertions, or

deletions (KO).

Numerous “genetic cassettes” can be

expressed at high levels.

0

45

90

180

135 225

270

315

Deinococcus main chromosome

Available sites

new sites in progress

Multi-targetting cassette

Specific targetting cassette

DEINOVE

Green chemicals do not

command price premiums in

the market:

Conversion rates and both products

and feedstock prices are key!

ADEME announced its support

of Deinove’s Terpenoids

production ambition:

$8.5MUSD in 2013.

DEINOL CONVERSION RATES

19

DEINOCHEM

Terpenoids:

Linalool, Geraniol and B-Pinene

Pathway Intermediates: Isopentene/isopentane Nutraceuticals:

Prebiotics: Xylitol and Fucosylated Sugars

Carotenoids

Green Chemicals:

Succinic Acid

PDO

Adipic Acid

HMD

MARKET OPPORTUNITIES

20

DEINOCHEM

DEINOCHEM program • Resources dedicated to the program

(2012 launch/2013 acceleration)

• Promising early work from our laboratories

• Advanced discussions with many world

leading industrials partners

The largest family of natural

substances in the world:

• More than 22,000 isoprene compounds

• Many industrial applications: creams,

fragrance, detergents, anti-cancer agents…

Looking for new production

standards:

• Extraction from plants and chemical

synthesis suffer from low yields and high

production costs

THE WAY TO ISOPRENOIDS

21

DEINOCHEM

HIGHER RESISTANCE TO ISOPRENOÏDS

22

IC50 (G/L) ISOPRENE GERANIOL LINALOOL b-PINENE

E. coli 7 0,6 4 91,7

S. cerevisiae 8 0,8 4 22,5

D. radiodurans

R1 21 No Inhibition 25 22,5

D. geothermalis

MX6-1E 12 7,8 5 ND

D. geothermalis

MX6-1C 14 No Inhibition 7 ND

D. geothermalis

MC2-2A 14 No Inhibition 7 ND

D. geothermalis

M36-7D 22 0,6 3 91,7

METABOLIZATION TEST (MTT)

DEINOCHEM

DEINOVE is now developing a brand new application platform named DEINOREDUCTION™

focused on the industrial bioreduction of various materials to produce high value renewable

compounds.

The first applications will be focused on the following opportunities:

23

Xylitol PDO, Isopropanol

and Butanol

Fucose and fucosylated

prebiotics

DEINOCHEM

C6 derivatives, ideally from a cellulosic carbon source: Adipic Acid: >6BUSD Market

C6 derivative, diamine for polyurethanes, nylon manufacturing.

HMD: >4BUSD Market

C6 derivative, dicarboxylic acid for polyesters, nylon manufacturing.

Terpenoid pathway intermediates as solvents or synthetics:

Isopentane: ~$2.5/Kg

Isopentene: ~$3/Kg

PRODUCTS OF INTEREST

24

DEINOCHEM

HIGHER RESISTANCE TO SOLVENTS

25

IC50 (G/L) ETHANOL DECANOL SERINOL HEXANOL BUTANOL BUTANOL ACRYLIC HEXANOIC

Gentle shaking Strong shaking ACID ACID

E. coli 43 6 46 4.5 24 89 0.3 0,2

S. cerevisiae 115 ND 93 ND 24 86 0.2 0,3

D. radiodurans

R1 294 7 404 17 96 107 1.2 3.9

D. geothermalis

MX6-1E 126 3

No

inhibition

No

inhibition 240 92 1 3.4

D. geothermalis

MX6-1C 118 4

No

inhibition 22.7 272 ND 0.9 3.6

D. geothermalis

MC2-2A 115 4

No

inhibition 12.3 184 ND 1 ND

D. geothermalis

M36-7D 125 2 ND 11.4 200 ND 1.9 2.6

METABOLIZATION TEST (MTT)

MERCI!!! THANK YOU!!!

26

CONTACTS

27

Emmanuel PETIOT CEO Tel : + 33 1 42 03 27 37 emmanuel.petiot@deinove.com

Jean-Paul LEONETTI VP R&D Tel : + 33 1 42 03 27 37 jean-paul.leonetti@deinove.com

Nagib M. WARD Vice President, Business Development

nagib.ward@deinove.com

CapTrust Tower, 4208 Six Forks Road, Suite 1000

Raleigh, NC 27609 USA

(O): +1 919-645-5784 (M): +1 609-772-2223 (F): +1 919-825-4801

DISCUSSION SUPPORT

OUR PROPRIETARY TECHNOLOGICAL PLATFORM

THE BEST OF GENETIC ENGINEERING AND BACTERIOLOGY

29

ARCHIVING

Library of cryopreserved

strains

Physiology

High-throughput growth assays

Metabolomic

Functional tests Gene expression

measurement

Microbiology

Genomic

PCR Sequencing & Annotation

DEINOBANK (6,000 clones)

Genetic & Metabolic

Engineering

Gene insertion Gene deletion

Sequence optimization

LAB PILOT

INDUSTRIAL PILOT

PRODUCTION

COLLECTION SELECTION OPTIMISATION SCALE UP

LEAD DEINOCOCCUS CANDIDATE

S1 S2 S3 POC

Fermentation engineering

Optimization of culture &

fermentation processes

Industrial engineering

Lab Assays Test &

Integration

Samples collection in

extreme environment